https://www.selleckchem.com/pr....oducts/bay-1895344-h
002), TNM stage (P = 0.02, tumour distant metastasis (P = 0.033), overall survival (OS) (P = 0.002) and progression-free survival (PFS) (P = 0.001). Multivariate analysis revealed that increased expression of syntenin was an independent risk factor for OS (P = 0.006) and PFS (P less then 0.001) in lung cancer patients. The expression levels of syntenin and VEGF in serum from lung cancer patients were higher than those from control subjects (P less then 0.001, P less then 0.001, respectively), and their expression levels
Like
Comment
Share
